The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 3 March 2009, www.theannals.com, DOI 10.1345/aph.1L502.
The Annals of Pharmacotherapy: Vol. 43, No. 3, pp. 459-468. DOI 10.1345/aph.1L502
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwo, E. C
Right arrow Articles by Steinman, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwo, E. C
Right arrow Articles by Steinman, M. A

MANAGED CARE

Physician Use of Brand Versus Generic Drug Names in 1993–1994 and 2003–2004

Elizabeth C Kwo, BA

Medical Student, Harvard Medical School/The Medical Student Training in Aging Research Program, University of California, San Francisco, CA

Priya Kamat, BA

Research Associate, Division of Geriatrics, San Francisco VA Medical Center/Northern California Institute for Research and Education/University of California, San Francisco

Michael A Steinman, MD

Division of Geriatrics, San Francisco VA Medical Center/University of California, San Francisco

Reprints: Dr. Steinman, Division of Geriatrics, San Francisco VA Medical Center/University of California, 4150 Clement St., Box 181-G, San Francisco, CA 94121, fax 415/750-6641, mike.steinman{at}ucsf.edu

BACKGROUND: Physicians often refer to drugs by their brand names, which can result in brand name drugs being dispensed even when bioequivalent generic alternatives are available. As a result, use of brand-name terminology may result in increased drug costs.

OBJECTIVE: To evaluate how often physicians use brand and generic names of drugs, how the use of terminology changes over time, and factors associated with this change.

METHODS: This was a serial cross-sectional study using data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey in 1993/1994 and 2003/2004. Over the 4 study years, data were collected on 376,383 subjects. Using forms completed by physicians that described medication regimens, we determined the proportion of drug names that were recorded using brand vs nonproprietary (ie, generic) terminology.

RESULTS: In 1993/1994, the 25 most commonly mentioned drugs were referred to by their brand names a median of 89% of the time. Over the ensuing decade, use of brand-name terminology decreased by a median of 11%. Drugs that first faced generic competition within 10 years of the baseline study year had large declines in brand-name use (43–58% decline), whereas drugs that first faced generic competition more than 10 years before or after the baseline study year had minimal change in brand-name use (2–3% decline; p = 0.02 for difference in rate of decline among drug groups). Year of drug introduction, baseline rate of brand-name use, clinical setting, and national region were not associated with reductions in brand-name use.

CONCLUSIONS: Brand-name terminology is commonly used and decreases over time with the introduction of generic competition. Interventions that standardize medication-naming practices may hasten this decline and increase use of nonproprietary terminology in medicine.

Key Words: brand names, generic names, pharmaceutical industry

Published Online, March 3, 2009. www.theannals.com, DOI 10.1345/aph.1L502





homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.